Secukinumab + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-radiographic Spondyloarthritis
Conditions
Non-radiographic Spondyloarthritis
Trial Timeline
Apr 29, 2016 → Mar 11, 2021
NCT ID
NCT02696031About Secukinumab + Placebo
Secukinumab + Placebo is a phase 3 stage product being developed by Novartis for Non-radiographic Spondyloarthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT02696031. Target conditions include Non-radiographic Spondyloarthritis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (19)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05722522 | Phase 3 | Terminated |
| NCT05758415 | Phase 3 | Terminated |
| NCT04737330 | Phase 3 | Terminated |
| NCT04732117 | Phase 3 | Completed |
| NCT04181762 | Phase 3 | Terminated |
| NCT04156620 | Phase 3 | Completed |
| NCT03713632 | Phase 3 | Completed |
| NCT03713619 | Phase 3 | Completed |
| NCT03055494 | Approved | Completed |
| NCT02896127 | Phase 3 | Completed |
| NCT02696031 | Phase 3 | Completed |
| NCT02599129 | Phase 2 | Terminated |
| NCT02594098 | Phase 2 | Completed |
| NCT02362789 | Phase 3 | Completed |
| NCT01989468 | Phase 3 | Completed |
| NCT02044848 | Phase 2 | Terminated |
| NCT01892436 | Phase 3 | Completed |
| NCT01807520 | Phase 3 | Completed |
| NCT01537432 | Phase 2 | Completed |
Competing Products
4 competing products in Non-radiographic Spondyloarthritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SUNPG1622 I dose + Placebo dose | Sun Pharmaceutical | Phase 2 | 52 |
| SHR0302 + SHR0302 placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Secukinumab + Placebo | Novartis | Phase 3 | 77 |
| Secukinumab + Placebo + Secukinumab | Novartis | Approved | 85 |